Background: The local and remote injury of pancreatitis resembles other inflammatory events that are mediated by complement. This study examines the effect of complement inhibition with sCR1 in ceruleininduced pancreatitis in rats.
Introduction
Acute pancreatitis is characterized by acinar cell injury and local edema with release of inflammatory mediators causing multisystem organ failure.
Systemic manifestations include respiratory, renal, and hepatic failure. Pulmonary complications are relatively common (1) with hypoxia in 50% of patients and, in some instances, the adult respiratory distress syndrome (ARDS). The pathophysiology of acute pancreatitis is unknown, but ethanol ingestion or cholelithiasis is associated in 80% of cases (2) .
Complement activation has been suspected to play a pathogenic role in experimental and clinical acute pancreatitis (3) (4) (5) (6) (7) (8) (9) . Local complement deposition is found with taurocholic acid-induced pancreatitis in the rat (9) , and a fall in serum lytic activity (CH50) and C3 levels are found in human pancreatitis (4) (5) (6) (7) (8) . Some authors suggest that complement activation is responsible for initiating acinar cell damage (9) and that it can cause ARDS in the setting ofpancreatitis or other local injuries (10) (11) (12) (13) (14) . Other investigators believe that, as a consequence ofpancreatitis, trypsin is released. This, then, is the primary agent of injury, and it also cleaves soluble complement components, so that complement, per se, is not involved in the pathogenesis ofpancreatitis (15) (16) (17) .
Many models ofpancreatitis have been developed including bile duct ligation, intraductal injections of bile acids and proteases, reflux of bile acid into the biliopancreatic duct, choline-deficient diet, and systemic infusion ofcerulein, a cholecystokinin analog (18) (19) (20) (21) . Hyperstimulation with supranormal doses of cholecystokinin is believed to cause organelle dysfunction and enzyme activation (22) . This results in edema, focal glandular necrosis, and an acute infiltrate morphologically similar to the reversible edematous pancreatitis seen in man.
Guice et al. have shown that cerulein-induced pancreatitis produces an ARDS-Iike lung injury with neutrophil sequestration and increased lung permeability (23) . The remote lung injury is ameliorated by the induction ofneutropenia, complement depletion using cobra venom, or by scavenging oxygen free radicals. Based on this data, they suggest that the injury involves complement activation with production of chemoattractants, such as C5a and C3a, in turn, leading to neutrophil activation with production of oxygen free radicals and resulting in local and remote endothelial damage with acute lung failure (24) .
This study directly tests the role of complement in both local and remote injuries following cerulein infusion by using soluble complement receptor type 1 (sCR1). Soluble CR1 is the truncated extracellular domain of CR1 and is a potent inhibitor of both the altemate and classical complement pathways by causing dissociation of C3 and C5 convertases (25) . In the doses employed, it has been successful in reducing the local injuries in rodent hindlimb and intestinal ischemia as well as the remote pulmonary injury (13, 14) .
Methods

Animal Preparation
Adult male, virus antibody free, Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA), 450-550 g, were anesthetized with ip sodium pentobarbital (65 mg/kg) and tail veins were cannulated. Anesthesia was maintained with iv pentobarbital, and the animals kept supine for the duration of the experiment.
Cerulein-Induced Pancreatitis
Pancreatitis was produced by five hourly injections ofcerulein (Sigma St. Louis, MO). At the start of the experiment, 100 jag/kg of cerulein was given subcutaneously followed by 50 gg/kg each hour. Identical volumes of subcutaneous normal saline injections were used as controls.
sCR1 Treatment
Animals were treated with hourly iv doses ofsCR 1 (T Cell Sciences, Cambridge, MA), 15 mg/kg. This dose previously has been shown to completely inhibit the classical and alternative complement pathways (13) . Concurrent use of the same batch of this agent in ischemia/reperfusion experiments produced a pronounced therapeutic benefit. Saline vehicle was administered as a control. Soluble CR1 was administered simultaneous to the cerulein injections.
Pancreatic and Liver Injury
At the end of the fifth hour, the animals were euthanased, a laparotomy was performed and ascites fluid was removed. The ascites volume was measured and assayed for amylase by a quantitative kinetic method involving the hydrolysis of 4,6-ethylidene [67]p-nitrophenyl [G1 ]-Gt,D-maltoeptaside to p-nitrophenol, which absorbs light at 405 nm (Sigma). The pancreas was immediately excised, blotted, weighed, and placed in a drying oven at 90~ for 3 d. The wet-to-dry weight ratio was calculated. The hematocrit was measured, as was the change in serum amylase and end serum SGPT assayed by a quantitative kinetic methods measuring the oxidation of reduced nicotinamide adenine dinucleotide spectrophotometrically at 340 nm (Sigma).
Lung Permeability
Prior to the cerulein injections, 0.5 mL of fluorescein isothiocyanate (FITC) conjugated albumin (Sigma) were given intravenously for lung permeability studies. At harvest, a thoracotomy was performed and a 5-mL sample of blood from the right ventricle removed, and the trachea, lungs, and heart excised en bloc. The left lung was lavaged with 3.3 mL of saline, three times, for a total of 10 mL. The fluorescence of the lavage fluid and serum was measured and converted to concentration of FITC-albumen using previously developed standard curves for bronchoalveolar lavage (BAL) fluid and serum. Lung permeability index (PI) was calculated from the ratio of the concentration of FITC-albumen in BAL fluid to the concentration of FITC-albumen in serum.
Myeloperoxidase Assay (MPO)
Pulmonary neutrophil sequestration was quantitated by an assay ofMPO. MPO is a heme-containing enzyme within the azurophil granules ofneutrophils that constitutes 5% of the cellular weight. MPO has previously been shown to correlate with neutrophil numbers and is a simple quantitative method to detect neutrophil sequestration (13, 14) .
The right lung was weighed, and I g of tissue was homogenized with 10 mL of 0.01MKH2PO 4 and 9 mM EDTA at pH 7.4. The homogenate was centrifuged at 10,000g at 4~ for 20 rain. The pellet was resuspended in 10 mL of 0.05M KH2PO 4 with 0.5% hexadecyltriethylammonium bromide at pH 6.0. This was frozen at-20~ overnight and then sonicated for 4 min and centrifuged at 10,000g for 20 min. The final supematant was collected for MPO.
The assay was performed at pH 5.4 at 37~ The mixture contained 0.4M KH2PO 4 (0.2 mL), 16 mM 3,Y,5,5'-tetramethylbenzidine in N,N-dimethylformamide (0.1 mL), 150 mMKH2PO 4 (0.5 mL), and 0.5 mL of the sample. The reaction was started by the addition of 3 mM H202 (0.1 mL) and stopped after 4 min with 0.002% bovine catalase (0.4 mL). Absorbance was measured spectrophotometrically at 655 nm (Spectronic 601, Milton Roy, Rochester, NY) and compared with a standard curve generated from human MPO (Sigma) to determine the units of MPO/gm of tissue (wet weight).
Statistical Analysis
Results are presented as the mean + SEM in the text and tables. All data was subjected to analysis of variance (ANOVA) and, when a significant difference was found, comparisons were performed using the nonpaired Students t-test with the Bonferonni correction.
Animals used in this study were maintained in accordance with the guidelines of the Committee on 
Results
Compared to saline, cerulein administration produced pancreatitis (Table 1 ). This was documented by an (p < 0.05) increase in wet-to-dry weight ratio of the pancreas (8.52 + 0.39 vs 3.25 + 0.09), a rise in serum amylase (10,700 + 777 vs 1680 + 55.5 U/L) and in ascites fluid amylase (167,000 + 14,000 vs 2,160 + 182 U/L), and an increased ascites volume (6.1 + 0.5 vs 2.1 + 0.2 mL). Cerulein also produced remote injury (Table 2) lung myeloperoxidase (0.097 + 0.008 vs 0.069 + 0.005 U/g, p < 0.05). Complement inhibition by sCR1 did not significantly reduce the pancreatic wet-to-dry ratio (8.85 + 0.29), rise in serum amylase (10,400 + 628 U/L), or rise in ascitic fluid amylase (166,000 + 10,300 U/L). There was a slight decrease in ascitic volume (4.8 + 0.9 mL) and a decrease in the hematocrit (45 + 1.4%), neither of which achieved statistical significance. There was a reduction in remote liver injury with SGPT 38.8 + 4.0 vs 46.6 + 3.1 U/L in untreated animals, but this also did not reach statistical significance. Remote lung injury was not changed with lung permeability 0.150 + 0.025, and lung myeloperoxidase at 0.086 + 0.007 U/g.
Discussion
The spectrum of disease in acute pancreatitis is broad, ranging from mild edematous pancreatitis, which is readily reversible and characterized by pancreatic edema, leukocyte infiltration, and hyperamylasemia to the extreme of severe necrotizing hemorrhagic pancreatitis characterized by acinar cell destruction, fat necrosis, and phlegmon formation with abscess (26, 2 7) . Systemic sequelae may include respiratory and hepatic failure (28) .
Since the etiology is unclear and the anatomy of the gland varies from species to species, the many models of pancreatitis have limited applicability to man. The question of whether the cholecystokinin analog (cerulein) mimics human disease is unclear. Arguments for its applicability are that increased levels of circulating cholecystokinin are noted in rats with bile-duct obstruction (29) , an event leading to pancreatitis in humans secondary to gallstones; however, hyperstimulation of the pancreas by cholecystokinin has not been proven in human pancreatitis, and attempts to block gastric acid secretion or delivery to the proximal small bowel (to suppress cholecystokinin secretion) or treatment with a cholecystokinin antagonist have not been successful in ameliorating the disease (30) (31) (32) .
Complement activation is suspected to participate in some forms of acute pancreatitis (3) (4) (5) (6) (7) (8) , with complement deposition around acinar cells following intraductal instillation of tauracholate (9) . The interpretive problem is that complement activation may cause pancreatitis (9) or be the result of pancreatitis (15, 16) . In either case, complement activation might lead to systemic consequences such as ARDS (10) (11) (12) (13) (14) . The goal of this study was to selectively inhibit complement and thereby test whether this would modify one or more components of this disease. Soluble CR1, a potent inhibitor of both the classical pathway and the alternative pathway (33) , was used in doses previously established to completely inhibit complement (13, 14) .
The mechanism of cerulein-induced pancreatitis is similar to diet-induced and duct obstructioninduced pancreatitis and involves colocalization of zymogen vacuoles and hydrolases causing intra-acinar cell enzyme activation and release into the parenchyma (22, 34) . This could lead to cleavage of complement proteins in the interstitium. Possible results of such complement activation might include direct acinar and endothelial cell damage with further enzyme release and vascular thrombosis. Indeed, reduced microcirculatory perfusion has been described by intravital microscopy in experimental pancreatitis (35) . In addition, complement cleavage products such as C5a or C3a might attract and stimulate neutrophils to release oxygen free radicals or elastase in the pancreas. None of these mechanisms nor other complement-dependent mechanisms appeared operative following cerulein infusion since sCR 1 had no effect on the local pancreatic injury. Other studies that have employed cobra venom factor to deplete complement have shown no affect on the local pancreatic disease (24) .
Cerulein-induced pancreatitis produced remote injury described by increased lung permeability, rise in serum SGPT, and hemoconcentration. This was associated with leukosequestration in the lung as measured by MPO. Since previous studies have shown that cerulein is not directly toxic to ex vivo lung preparations (23) , the remote injury may be owing to systemic release of inflammatory mediators, following or leading to neutrophil and complement activation. Soluble CR1 treatment resulted in a trend toward reduction in remote liver dysfunction. Lung injury and neutrophil sequestration were not affected. This indicates that complement played at most a minor role in the mediation of remote injury following cerulein-induced pancreatitis.
The explanations for our disparate finding relative to other investigators are conjectural. The significant reduction in remote lung injury with cobra venom factor-induced complement depletion (24) may relate to the different method employed to inactivate complement. Two days before the experiment, cobra venom factor was administered. This initially activates and thereby depletes complement. Complement-derived anaphylotoxins such as C3a and C5a circulate, activate neutrophils (36) and produce neutropenia (3 7) . Repeated stimulation of neutrophils with chemoactivators such as C5a will alter neutrophil function such as diapedesis and subsequent chemotaxis to C5a (38) . Thus, cobra venom factor may have a more important effect for this pancreatitis model by reducing neutrophil number and function as well as the intended effect on complement. Soluble CR1 specifically inhibits the classical and alternative complement pathways by dissociating the C3 and C5 convertases (25) and does not modify neutrophil function as no anaphylatoxins are generated. If neutrophils are key inducers of remote injury, cobra venom factor but not sCR1 might therefore be expected to reduce that injury.
In summary, our data indicate that complement is not involved in the pathogenesis of ceruleininduced pancreatitis. Further remote lung and liver injury are minimally affected by complement inactivation.
